Getting an elevated Lp(a) test result encourages patients with coronary heart disease (CHD) to make more effort to reduce their overall risk of cardiovascular disease (CVD) and makes them want close relatives to get tested too. However, most are unaware that the Lp(a) level is inherited and cannot be modified by lifestyle, and they think it can be reduced by medication. These were some of the findings reported from the INTERASPIRE study of CHD secondary prevention at ESC 2025 and published in the European Journal of Cardiovascular Nursing.1,2
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.